40 Participants Needed

IO vs IV Vancomycin for Preventing Infection in Knee Surgery

TC
HG
Overseen ByHaley Goble, MHA
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: The Methodist Hospital Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. However, if you are on immunosuppressive medications, you may not be eligible to participate.

What data supports the effectiveness of the drug Vancomycin in preventing infection in knee surgery?

Research shows that using vancomycin directly in the bone (intraosseous) during knee surgery can lead to higher local antibiotic levels compared to traditional IV methods, potentially reducing infection rates. Additionally, intraosseous vancomycin has been associated with lower rates of joint infections after knee surgery without increasing complications.12345

Is intraosseous vancomycin safe for use in knee surgery?

Research shows that using intraosseous vancomycin in knee surgery does not increase the risk of complications compared to the traditional intravenous method, suggesting it is generally safe for humans.12367

How is the drug vancomycin used differently in this knee surgery trial?

In this trial, vancomycin is administered intraosseously (directly into the bone), which allows for higher local tissue concentrations compared to the traditional intravenous (IV) method, potentially improving its effectiveness in preventing infections during knee surgery.13589

What is the purpose of this trial?

This trial is comparing two methods of giving an antibiotic during knee replacement surgery: through a vein and directly into the bone. It aims to see which method helps the antibiotic reach the knee area better and if it affects infection rates after surgery. Delivering antibiotics directly into the bone achieves higher local concentrations with fewer side effects and has been shown to be more effective for preventing infection following surgery.

Eligibility Criteria

This trial is for adults over 18 who are having their first knee replacement surgery without a tourniquet. They must understand the study and agree to participate. It's not for people with weak immune systems, uncontrolled diabetes (Hemoglobin A1C >7.5), allergies to vancomycin or similar antibiotics, BMI over 35, or those who've had previous knee surgeries.

Inclusion Criteria

Patient is undergoing a primary total knee arthroplasty.
Patient is able to understand the study design and intervention and gives informed consent to participate in the study. No LAR consents will be utilized for this study.
You had knee surgery without the use of a tourniquet.

Exclusion Criteria

Immunocompromised or immunosuppressed patients (HIV, Hep C, End-Stage Renal Disease, dialysis, transplant, chemo/radiation treatment in last 6 months, and immunosuppresive medications)
Uncontrolled Diabetes Mellitus type 1 or 2, defined as Hemoglobin A1C >7.5.
Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo total knee arthroplasty with either intraosseous or intravenous vancomycin administration

Immediate post-op
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including 30-day and 90-day post-operative complication rates

90 days
Multiple visits (in-person) as per standard of care

Treatment Details

Interventions

  • Vancomycin
Trial Overview The study compares two ways of giving antibiotics during knee replacement surgery: directly into the bone (intraosseous) vs. into a vein (intravenous). The goal is to see which method better prevents infections after surgery without using a tourniquet.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intraosseous Vancomycin AdministrationExperimental Treatment1 Intervention
* IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision. IV Vancomycin will not be administered preoperatively in this group. * IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS). * Injection will take place into the tibial tubercle (within a pre-specified region) immediately prior to incision.
Group II: Intravenous Vancomycin AdministrationActive Control1 Intervention
Patients will receive the Houston Methodist Hospital orthopedic surgery standard of care pre-operative antibiotic regimen for primary total knee arthroplasty patients. This includes IV antibiotics (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[12,13\] generally 1000-1750mg in 500mL NS).

Vancomycin is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸
Approved in United States as Vancocin for:
  • Severe infections caused by susceptible strains of methicillin-resistant staphylococci
  • Enterocolitis caused by Staphylococcus aureus
  • Staphylococcal endocarditis
🇪🇺
Approved in European Union as Vancomycin for:
  • Severe infections caused by Gram-positive bacteria
  • Endocarditis
  • Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD)
🇨🇦
Approved in Canada as Vancomycin for:
  • Severe infections caused by susceptible strains of methicillin-resistant staphylococci
  • Enterocolitis caused by Staphylococcus aureus
🇯🇵
Approved in Japan as Vancomycin for:
  • Severe infections caused by Gram-positive bacteria
  • Endocarditis

Find a Clinic Near You

Who Is Running the Clinical Trial?

The Methodist Hospital Research Institute

Lead Sponsor

Trials
299
Recruited
82,500+

References

Clinical outcome evaluation of intraosseous vancomycin in total knee arthroplasty. [2022]
2021 Chitranjan S. Ranawat Award: Intraosseous vancomycin reduces periprosthetic joint infection in primary total knee arthroplasty at 90-day follow-up. [2021]
Intraosseous Regional Administration of Vancomycin in Primary Total Knee Arthroplasty Does Not Increase the Risk of Vancomycin-Associated Complications. [2021]
Intraarticular vancomycin decreased the risk of acute postoperative periprosthetic joint infection without increasing complication in primary total joint arthroplasty-a prospective study. [2023]
Vancomycin concentration in synovial fluid: direct injection into the knee vs. intravenous infusion. [2014]
Efficacy and safety of intrawound vancomycin in primary hip and knee arthroplasty. [2020]
Decrease in acute periprosthetic joint infections incidence with vancomycin-loaded calcium sulfate beads in patients with non-modifiable risk factors. A randomized clinical trial. [2022]
Otto Aufranc Award: Intraosseous Vancomycin in Total Hip Arthroplasty - Superior Tissue Concentrations and Improved Efficiency. [2023]
A systematic review and meta-analysis comparing intrawound vancomycin powder and povidone iodine lavage in the prevention of periprosthetic joint infection of hip and knee arthroplasties. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security